Table 2. Comparison of Clinical Characteristics of Patients in Arm A and Arm B a .
Total (n = 1698) | Arm A (n = 542) | Arm B (n = 1156) | p value | ||||
---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | |||||
Age, years (mean ± SD) | 58.2 ± 12.8 | 58.4 ± 12.3 | 58.1 ± 13.0 | 0.67 b | |||
<40 | 133 | (7.8) | 34 | (6.3) | 99 | (8.6) | 0.23 c |
40−59 | 755 | (44.5) | 240 | (44.3) | 515 | (44.6) | |
≥60 | 810 | (47.7) | 268 | (49.4) | 542 | (46.9) | |
Gender | 0.95 c | ||||||
Female | 738 | (43.5) | 235 | (43.4) | 503 | (43.5) | |
Male | 960 | (56.5) | 307 | (56.6) | 653 | (56.5) | |
CCI (mean ± SD) | 0.8 ± 1.3 | 0.7 ± 1.1 | 0.8 ± 1.4 | 0.78 b | |||
0 | 1026 | (60.4) | 315 | (58.1) | 711 | (61.5) | 0.18 c |
1−2 | 513 | (30.2) | 180 | (33.2) | 333 | (28.8) | |
≥3 | 159 | (9.4) | 47 | (8.7) | 112 | (9.7) | |
Hypertension | 0.68 c | ||||||
No | 1182 | (69.6) | 381 | (70.3) | 801 | (69.3) | |
Yes | 516 | (30.4) | 161 | (29.7) | 355 | (30.7) | |
Diabetes | 0.95 c | ||||||
No | 1455 | (85.7) | 464 | (85.6) | 991 | (85.7) | |
Yes | 243 | (14.3) | 78 | (14.4) | 165 | (14.3) | |
Hyperlipidemia | 0.22 c | ||||||
No | 1469 | (86.5) | 477 | (88.0) | 992 | (85.8) | |
Yes | 229 | (13.5) | 65 | (12.0) | 164 | (14.2) | |
CVD | 0.90 c | ||||||
No | 1077 | (63.4) | 345 | (63.7) | 732 | (63.3) | |
Yes | 621 | (36.6) | 197 | (36.3) | 424 | (36.7) | |
CKD | 0.46 c | ||||||
No | 1681 | (99.0) | 538 | (99.3) | 1143 | (98.9) | |
Yes | 17 | (1.0) | 4 | (0.7) | 13 | (1.1) |
aArm A, irinotecan followed by oxaliplatin-based regimens; arm B, oxaliplatin followed by irinotecan-based regimens.
SD: standard deviation; CCI: Charlson comorbidity index; CVD: cardiovascular disease; CKD: chronic kidney disease.
bStudent’s t-test for continuous variables
cChi-square test for categorical variables.